Skip to main content

Table 1 Patient demographic and tumour characteristics

From: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

  

n = 32(%)

Age, mean ± SD

 

53.6 ± 12.2

Hormone receptor

positive

14 (43.8)

negative

18 (56.2)

TNBC

 

16 (50)

PS

0

19 (59.4)

1

13 (40.6)

Prior treatment

Anthracycline

23 (71.9)

Taxane

29 (90.6)

Prior regimen number

0

11 (34.4)

1

14 (43.8)

2

7 (21.9)

Visceral metastasis

present

22 (68.8)

Number of metastases

1

28 (87.5)

2

2 (6.3)

3

1 (3.1)

4

1 (3.1)

Metastatic sites

Liver

14

Lymph node

10

Lung

8

Skin

3

Pleural

1

Breast

1

Thyroid

1

Spleen

1

  1. Abbreviations: OR Oestrogen receptor, PgR Progesterone receptor, HER-2 Human epidermal growth factor receptor 2, PS Performance status